Metformin Shows Promise for Increasing NSCLC Survival

by U.S. Medicine

November 9, 2017

BETHESDA, MD—Past research has raised the possibility that a common blood sugar-lowering drug could be associated with improved survival in cancer patients with Type 2 diabetes.

A study published recently in the International Journal of Cancer assessed whether metformin use is associated with overall survival among Type 2 diabetic patients diagnosed with non-small cell lung cancer (NSCLC) in the MHS.1

Data from the linked database of the DoD’s Central Cancer Registry (CCR) and the MHS Data Repository (MDR) were employed for the study led by researchers from the John P. Murtha Cancer Center at Walter Reed National Military Medical Center in Bethesda.

Included were 636 patients with diabetes who also had histologically confirmed NSCLC diagnosed between 2002 and 2007. During the median follow-up time of 14.6 months, 411 of the patients died.

Results indicated that increased postdiagnosis cumulative use (per one year of use) of metformin conferred a significant reduction in mortality, for an adjusted hazard ratio (HR) of 0.76. Upon further analysis by duration of use, researchers determined that, compared to nonusers, the lowest risk reduction occurred among patients with the longest duration of use—i.e., use for more than two years—for an HR of 0.19.

In addition, the study authors pointed out, reduced mortality was particularly observed only among patients who also used metformin before lung cancer diagnosis and among patients at early Stage of diagnosis.

“Prolonged duration of metformin use in the study population was associated with improved survival, especially among early Stage patients,” the study team concluded. “Future research with a larger number of patients is warranted.”

1 Lin J, Gill A, Zahm SH, Carter CA, Shriver CD, et. al. Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system. Int J Cancer. 2017 Jul 15;141(2):254-263. doi: 10.1002/ijc.30724. Epub 2017 May 4. PubMed PMID: 28380674.

Comments are closed here.

Related Articles

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Caution Urged in Use of Sulfonylureas in Some T2 Diabetes Patients with CAD

VA clinicians should exercise caution with use of sulfonylurea in some patients with co-morbid type 2 diabetes and cardiovascular disease, according to new research.

U.S. Medicine Recommends

More From oncology


Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?


Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.


VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.


VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.


Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up